The global multiple myeloma market is experiencing steady expansion, driven by increasing disease awareness, advances in cancer treatment, and the development of innovative therapies.
According to Fortune Business Insights, the global multiple myeloma market size was valued at USD 29.24 billion in 2025. The market is projected to grow from USD 31.00 billion in 2026 to USD 49.79 billion by 2034, registering a CAGR of 6.10% during the forecast period.
Multiple myeloma is a type of blood cancer that develops in plasma cells, a type of white blood cell responsible for producing antibodies. Growing investments in oncology research, improvements in diagnostic technologies, and the introduction of targeted and immune-based treatments are contributing to the expansion of the multiple myeloma treatment landscape.
One of the key factors supporting the growth of the multiple myeloma market is the increasing adoption of advanced treatment options. Healthcare providers are increasingly using combination therapies and targeted approaches to improve treatment outcomes and manage the disease more effectively.
The treatment landscape includes several therapeutic approaches, including chemotherapy, targeted therapies, immunomodulatory drugs, monoclonal antibodies, corticosteroids, and other emerging treatment options. Continuous research and development activities are also encouraging pharmaceutical companies to introduce innovative therapies for patients with relapsed or refractory multiple myeloma.
The development of treatments that target specific mechanisms involved in cancer-cell growth has further expanded therapeutic options. In addition, increasing clinical research into novel drug combinations and immune-based approaches is expected to create new opportunities for market participants.
North America dominated the multiple myeloma market with a market share of 58.28% in 2025. The region's leading position can be attributed to the presence of advanced healthcare infrastructure, high adoption of innovative cancer therapies, significant healthcare expenditure, and strong pharmaceutical and biotechnology research capabilities.
The U.S. represents an important market within North America due to the availability of advanced oncology treatment centers and the presence of major pharmaceutical companies. Clinical research, regulatory developments, and the adoption of novel therapies also contribute to the region's strong market position.
Meanwhile, Europe and Asia Pacific are expected to provide significant opportunities for market participants. Increasing healthcare investments, improving access to cancer treatment, and growing awareness of multiple myeloma are supporting market development in these regions.
The global multiple myeloma market is highly competitive, with major pharmaceutical companies investing in research, drug development, clinical trials, and commercialization of advanced therapies. Key players include Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Amgen Inc., ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceuticals, Inc., Genentech, Inc., AbbVie Inc., Sanofi, and Karyopharm.
Takeda Pharmaceutical Company Limited is a major global pharmaceutical company with a strong presence in oncology. The company has developed and commercialized therapies used in the treatment of multiple myeloma. Its focus on innovative oncology treatments contributes to its position in the competitive market.
Novartis AG is a global pharmaceutical company with an extensive oncology portfolio. The company focuses on developing innovative medicines for cancer and other serious diseases. Its oncology research activities support the evolving multiple myeloma treatment landscape.
Teva Pharmaceutical Industries Ltd. is a major pharmaceutical company with operations across multiple therapeutic areas. Its portfolio includes medicines used in cancer care, supporting its participation in the broader multiple myeloma treatment market.